Resource

Nearly 12% of adults in the United States have reported using a GLP-1 agonist. The benefits of weight loss, appetite control, reduced inflammation and improved metabolic health is often overshadowed by the severe side effects of nausea, vomiting, diarrhea, bloating, acid reflux, stomach aches, headache, fatigue, dizziness and reduced appetite. In order to minimize these side effects many companies are microdosing these compounds with the additional advantage of reducing the cost of the treatment. These microdoses can be up to 20-fold lower than the typical therapeutic range. This dose reduction will result in clinical studies that must be conducted in order to determine the PK and efficacy of these compounds.

The bioanalysis of these compounds can be challenging since the assay sensitivity must be up to 20-fold lower than the previous methods. The presentation will explain the practical aspects of sample preparation and LC-MS/MS analysis to simultaneously measure semaglutide, liraglutide, exenatide and taspoglutide to support GLP-1 agonist microdosing clinical studies.